Partners4Access joins biotech trade association, BIA
Partners4Access has announced its membership of the UK’s leading biotechnology focused industry group, BioIndustry Association (BIA).
BIA represents several stakeholders within the biosciences area from small clinical stage biotechs, large pharma corporations, academics and service providers to the biotech industry. Their members account for majority of biotech drugs currently in clinical development. BIA is a leading voice in highlighting the UK life science industry’s challenges in innovation, research and development.
Sophie Schmitz, President and Managing Partner, P4A said, “ BIA and P4A share the same values of bringing together different stakeholders in the healthcare industry to deliver healthcare solutions that can truly make a difference to people’s lives. I am very excited to be working with them.”
Alison Kneen, Vice President, International Operations, P4A commented “I am delighted to be part of BIA and have seen first-hand the group’s impact in enabling dialogue on world-class research at their recent Women in Biotech networking event which was truly inspirational”.
P4A are specialists in orphan drug access, partnering with the biotechnology industry to support launches worldwide. Focus areas include: orphan drugs pricing and market access strategy; bespoke access roadmap; rare disease foresights; evidence mitigation solutions; access team excellence. As one of the only consultancies with comprehensive experience in cell and gene therapies, P4A are excellently placed to help clients successfully achieve access.
Through its initiatives, P4A are able to inform and shape the conversation around orphan drugs.
The team at P4A believe in striking an equilibrium in the rare disease world. That means helping drive access to the most appropriate treatments for patients and physicians, a fair return on investment for manufacturers at an affordable proposition for payers.
For more information, please email P4A at email@example.com.
About the BIA
Established over 25 years ago at the infancy of biotechnology, the BioIndustry Association (BIA) is the trade association for innovative enterprises involved in UK bioscience. Members include emerging and more established bioscience companies; pharmaceutical companies; academic, research and philanthropic organisations; and service providers to the bioscience sector. The BIA represents the interests of its members to a broad section of stakeholders, from government and regulators to patient groups and the media. Our goal is to secure the UK’s position as a global hub and as the best location for innovative research and commercialisation, enabling our world-leading research base to deliver healthcare solutions that can truly make a difference to people’s lives.
For further information, please go to www.bioindustry.org